AI-generated summary
The authors conducted a systematic review of randomized clinical trials on photobiomodulation for chronic pain in adults, including 14 studies. They report that most trials showed significant pain reduction, particularly in fibromyalgia and neuropathy, with low rates of adverse events. They note that heterogeneous technical parameters and limited follow-up hinder firm recommendations.
- Studies included
- 14
- Who or what was studied
- Adults with chronic pain conditions, including fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain
- Limits stated in the abstract
- The abstract cites heterogeneity of technical parameters, limited follow-up, and the need for standardized multicenter studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Introduction
Photobiomodulation (PBM) stands out as a promising therapeutic alternative for the management of chronic pain, but there is still controversy regarding its efficacy and safety, given the diversity of protocols and populations evaluated.
Objectives
To critically review the available literature on the use of PBM in adults with chronic pain conditions, synthesizing the evidence on analgesic and functional effects, impact on quality of life, and safety profile.
Methods
A systematic search was conducted in PubMed, Embase, Scopus, LILACS, and MEDLINE, including articles published between September 2015 and September 2025. Randomized clinical trials that compared PBM protocols to placebo, sham, or conventional care were selected. The outcomes investigated included pain intensity (primary), function, quality of life, and occurrence of adverse events (secondary).
Results
Fourteen studies were included, covering populations with fibromyalgia, peripheral neuropathies, orofacial pain, and musculoskeletal pain. Most trials demonstrated significant pain reduction with PBM, particularly in fibromyalgia and neuropathy. In some studies, functional gains and improved quality of life were observed. The incidence of adverse events was low, reinforcing the method's safety, although the heterogeneity of technical parameters compromises the standardization of results.
Conclusion
PBM has analgesic potential and a safe profile for managing chronic pain, especially in cases difficult to control with conventional therapies. However, the variability of clinical parameters and limited follow-up still hinder more comprehensive recommendations. Additional multicenter studies with standardized protocols are needed to consolidate clinical guidelines. SYSTEMATIC REVIEW
Registration
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251140711, Identifier: CRD420251140711.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Systematic review, Fibromyalgia, Heterogeneity, Neuropathy, Sham. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.